The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSomero Regulatory News (SOM)

Share Price Information for Somero (SOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 335.00
Bid: 330.00
Ask: 340.00
Change: -3.00 (-0.90%)
Spread: 10.00 (3.03%)
Open: 335.00
High: 332.00
Low: 332.00
Prev. Close: 335.00
SOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

31 Jan 2023 07:00

RNS Number : 3080O
Somero Enterprises Inc.
31 January 2023
 

31 January 2023

Somero Enterprises, Inc.

("Somero" or "the Company")

Trading Update

Record revenues driven by a healthy North American market, significant contributions from Europe and Australia

Somero® provides the following update on trading for the financial year ended 31 December 2022 ("the Period").

The Board is pleased to report that with strong, profitable trading and excellent operational performance in delivering global customer orders during H2 2022, it expects the Company to report 2022 revenue of approximately US$ 134.0m. This is a new record for the Company, surpassing 2021 revenues of US$ 133.3m, which in turn grew a remarkable 50% over 2020.

This 2022 revenue expectation falls modestly below previous guidance of US$ 138.8m, reflecting the impact, albeit limited, of supply chain shortages in our North America market on our customers' pace of work. This risk was noted in the Company's 7 September 2022 interim results release. 

Commensurate with the level of expected revenue, the Board expects the Company to report annual adjusted EBITDA of approximately US$ 46.0m, modestly below previous guidance of US$ 47.7m, and expects the Company to report ending cash of approximately US$ 34.0m, with some impact from the timing of tax refunds and working capital investment. These estimates remain subject to any audit adjustments.

Regional Breakdown

Trading in North America during the second half of 2022 reflected a healthy and active underlying non-residential construction market, although H2 2022 trading was somewhat down from H1 2022. On a full-year basis, trading was slightly down albeit from the record setting 2021 revenue of US$ 106.7m. This was due in large part to supply chain shortages, most notably the inconsistent availability of concrete nationwide that stems from a shortage of cement and drivers to transport material to job sites, that have slowed the pace of customers' work on certain projects. As we move into 2023, while it is difficult to predict when and to what extend the aforementioned challenges will ease, underlying market conditions in North America remain positive, with customers reporting a significant volume of work comparable to 2022 levels and extended project backlogs.

H2 2022 trading in Europe increased significantly from H1 2022 and grew on a full-year basis by over 20% from the US$ 12.1m reported in 2021. 2022 reported revenues in Europe are a record for the region, surpassing the previous high of approximately US$ 14.0m (US$ 10.1m on a constant currency basis) recorded in 2007. Trading during H2 2022 benefitted from a healthy non-residential construction market along with increased availability of inventory and the positive impact of the previously announced strategic shift internationally to focus on, and allocate resources, to the European and Australian markets.

In Australia, we expect to report increased H2 2022 revenues compared to H1 2022, growing nearly 40% on a full-year basis compared to the US$ 6.1m reported in 2021. This again represents a record performance. Trading during H2 2022 reflected a high-level of non-residential construction activity, increased availability of inventory, and the positive impact of increased selling and support staff in the market following the Company's decision to go direct at the end of 2020. 

We expect to report that H2 2022 revenue in China grew modestly from H1 2022 as COVID restrictions lessened in the second half of the year. As expected, following the previously announced shift in the Company's international strategy away from China, full-year revenue in the region declined by over 50% from the US$ 2.7m reported in 2021, amounting to only a modest contribution to the Company's annual 2022 revenues.

H2 2022 trading activity in the remaining regions, the most significant of which are India, Latin America, the Middle East, grew modestly on a combined basis compared to H1 2022 and on a full-year basis compared to 2021. Market conditions across these regions were positive during the second half of the year and remain so entering 2023.

Product Breakdown

On a product basis, H2 2022 trading in the Boomed-screed product line grew slightly compared to H1 2022 and on a full-year basis compared to 2021. This was driven by sales of the S-28EZ, the Company's largest machine. The success of the S-28EZ is a result of the Company's commitment to improving and adding value to its core existing product offering, which sits alongside its innovation strategy for entirely new solutions. 

H2 2022 trading across all other product lines, including Ride-on screed equipment, was balanced reflecting healthy diversity in the size of and type of customer projects. On a combined basis, whilst H2 2022 revenue across all products excluding Boomed-screeds was down modestly from H1 2022, we expect to report 2022 revenue at a comparable level to FY 2021.

2022 revenues from newer products released since 2019 that target entirely new market segments, including the SkyScreed, SkyStrip®, S-PS50, and Somero Broom+Cure, grew modestly on a combined basis from 2021 to contribute approximately US$ 4.0m to 2022 revenue. The Company remains focused on gaining traction in these new markets with the understanding the pace of market adoption for these disruptive products takes time. 

Strategy Update

Led by Europe and Australia, full-year 2022 revenue outside North America on a combined basis grew nearly 20% compared to 2021. This meant the contribution to revenue from international markets grew to approximately 24% of total sales compared to 20% in 2021. The 2022 growth is the direct result of the shift in international focus to Europe and Australia and the addition of key sales and support personnel to these markets. The Company continues to see an attractive international growth opportunity from new customers and new products, particularly in Europe and Australia. 

In Q4 2022, the Company completed the US$ 9.5m project to add 50,000 square feet to the Houghton, Michigan facility and expects the expansion will be fully operational in early Q1 2023. Completion of this project is essential to Company's longer-term growth strategy adding manufacturing capacity and workflow efficiencies while expanding in-house engineering capabilities.

Outlook

The Board is pleased with the strong finish to 2022 and looks forward to 2023 with confidence based on the strength of the US market, direct feedback from our customer base on activity, and the growth opportunity in Europe and Australia and from new products. To capture this opportunity, the Company remains committed to adding product development, sales, and support resources; a necessary near-term investment and cost with longer-term benefit.

With consideration to these factors, the Board expects 2023 will be a highly profitable year with healthy cash generation, revenues that are comparable to 2022, and EBITDA that reflects the planned investment to add strategic resources for future growth. 

Somero's final 2022 results announcement is scheduled for release on 8 March 2023.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as retained as part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the publication of this Announcement, this inside information is now considered to be in the public domain.

 

Enquiries:

 

 

Somero Enterprises, Inc.

Jack Cooney, CEO

John Yuncza, President

Vincenzo LiCausi, CFO

Howard Hohmann, EVP Sales

 

 

www.somero.com

+1 239 210 6500

finnCap Ltd (NOMAD and Broker)

Matt Goode (Corporate Finance)

Seamus Fricker (Corporate Finance)

Fergus Sullivan (Corporate Finance)

Tim Redfern (ECM)

Harriet Ward (ECM)

 

+44 (0)20 7220 0500

 

 

Alma PR (Financial PR Advisor)

David Ison

Pippa Crabtree

somero@almapr.co.uk

 +44 (0)20 3405 0205

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKKBNABKDCDN
Date   Source Headline
24th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
12th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
10th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
8th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
5th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
4th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Mar 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 20246:06 pmRNSTransaction in Own Shares and Total Voting Rights
19th Mar 20243:07 pmRNSRestricted Stock Units& Director/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
7th Feb 20247:00 amRNSNotice of Investor Presentation
31st Jan 20247:00 amRNSTrading Update
5th Jan 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
4th Jan 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
13th Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Nov 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
14th Nov 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
26th Oct 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
19th Oct 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
6th Oct 20237:55 amRNSTransaction in Own Shares and Total Voting Rights
2nd Oct 20237:00 amRNSBoard Change
27th Sep 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Sep 20238:49 amRNSTransaction in Own Shares and Total Voting Rights
18th Sep 20237:00 amRNSDirector/PDMR Shareholding & Change of NOMAD name
13th Sep 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
31st Aug 20237:00 amRNSInterim Results
29th Aug 20237:00 amRNSBoard Change
8th Aug 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Aug 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
31st Jul 20237:00 amRNSNotice of Investor Presentation
24th Jul 20237:00 amRNSTrading Update
5th Jul 20234:52 pmRNSTransaction in Own Shares and Total Voting Rights
4th Jul 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Jun 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Jun 20237:00 amRNSTrading Update
14th Jun 20233:46 pmRNSTransaction in Own Shares and Total Voting Rights
12th Jun 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
18th May 20233:10 pmRNSResult of AGM
17th May 20236:10 pmRNSTransaction in Own Shares and Total Voting Rights
17th May 20237:00 amRNSAGM Statement
12th May 20232:26 pmRNSTransaction in Own Shares and Total Voting Rights
4th May 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
26th Apr 20236:15 pmRNSUpdate re: RSUs & Director/PDMR Shareholding
26th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.